Editing Transplant rejection (section)

===Antibody-based treatments===

Antibody specific to select immune components can be added to immunosuppressive therapy. The [[monoclonal antibody|monoclonal]] anti-T cell antibody [[OKT3]], once used to prevent rejection, and still occasionally used to treat severe acute rejection, has fallen into disfavor, as it commonly brings severe [[cytokine release syndrome]] and late [[post-transplant lymphoproliferative disorder]]. (OKT3 is available in the [[United Kingdom]] for named-patient use only.)

'''Antibody drugs''':
* Monoclonal anti-IL-2Rα receptor antibodies
** [[Basiliximab]]
** [[Daclizumab]]
* Monoclonal anti-IL-6R receptor antibodies
** [[Tocilizumab]]
* Polyclonal anti-T-cell antibodies
** [[Anti-thymocyte globulin]] (ATG)
** [[Anti-lymphocyte globulin]] (ALG)
* Monoclonal anti-CD20 antibodies
** [[Rituximab]]